EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

AMPK signaling in cancer: Molecular insights and therapeutic opportunities

Weiwei Jiang, Peiqiang Yan, Jingchao Wang, Xutong Xue, Daoyuan Huang, Li Chen, Yuelin Yang, Hiroyuki Inuzuka, Wenyi Wei

Cancer Letters · 2026-12 · 662 · 218912

DOI: 10.1016/j.canlet.2026.218912 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026-12. Verfasst von Weiwei Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA. Hauptthemen laut MEDLINE: Neoplasms, Signal Transduction, AMP-Activated Protein Kinases. Die Arbeit nennt 171 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AMP-activated protein kinase (AMPK) is a highly conserved serine/threonine kinase regarded as an indispensable energy sensor during metabolic stress, coordinating diverse biological processes, including glycolysis, the tricarboxylic acid (TCA) cycle, mitochondrial dynamics, and multiple stress-responsive signaling pathways. Growing evidence shows that dysregulated AMPK signaling plays closely linked roles in tumorigenesis. Depending on the context, AMPK signaling can suppress or promote tumor growth. Mechanistically, dysregulated AMPK kinase activity contributes to metabolic reprogramming, mitochondrial dysfunction, and epigenetic alterations, all recognized hallmarks of cancer. Consequently, targeting AMPK signaling has emerged as a promising strategy for cancer therapy. In this review, we summarize the molecular mechanisms regulating AMPK signaling, discuss its dual functions in tumor biology, highlight recent advances in AMPK-targeted therapeutic strategies, and address current challenges and future perspectives for the clinical translation of AMPK-targeted cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsSignal TransductionAMP-Activated Protein KinasesHumansAnimalsMetabolic ReprogrammingMolecular Targeted TherapyEnergy MetabolismAntineoplastic AgentsMitochondria

Stichwörter der Autor:innen

AMPKCancer therapyEnergy sensorPost-translational modificationTumor metabolism

Substanzen

AMP-Activated Protein KinasesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
  • Department of Neurology & F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  • Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
  • Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA. Electronic address: wwei2@bidmc.harvard.edu.

Förderung

  • NCI NIH HHS
  • National Institutes of Health National Cancer Institute

Zitieren

APA

Jiang, W., Yan, P., Wang, J., Xue, X., Huang, D., Chen, L., Yang, Y., Inuzuka, H., & Wei, W. (2026). AMPK signaling in cancer: Molecular insights and therapeutic opportunities. Cancer Letters, 662, 218912. https://doi.org/10.1016/j.canlet.2026.218912

Vancouver

Jiang W, Yan P, Wang J, Xue X, Huang D, Chen L, et al. AMPK signaling in cancer: Molecular insights and therapeutic opportunities. Cancer Letters. 2026;662:218912. doi:10.1016/j.canlet.2026.218912

BibTeX
@article{Jiang2026,
  author = {Jiang, Weiwei and Yan, Peiqiang and Wang, Jingchao and Xue, Xutong and Huang, Daoyuan and Chen, Li and Yang, Yuelin and Inuzuka, Hiroyuki and Wei, Wenyi},
  title = {AMPK signaling in cancer: Molecular insights and therapeutic opportunities},
  journal = {Cancer Letters},
  year = {2026},
  volume = {662},
  pages = {218912},
  doi = {10.1016/j.canlet.2026.218912}
}
Kostenlos starten →